Second-generation tyrosine kinase inhibitors: The future of frontline CML therapy

Hagop M. Kantarjian, Michele Baccarani, Elias Jabbour, Giuseppe Saglio, Jorge E. Cortes

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations

Fingerprint Dive into the research topics of 'Second-generation tyrosine kinase inhibitors: The future of frontline CML therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences